Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M; Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP).
Haggstrom L, et al. Among authors: dong j.
JAMA Oncol. 2026 Aug 1;12(8):845-854. doi: 10.1001/jamaoncol.2026.1924.
JAMA Oncol. 2026.
PMID: 42348196
Free PMC article.